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Purpose: We present planning and early clinical outcomes of a study of intensity-modulated radiotherapy (IMRT)
for locally advanced prostate cancer.
Methods andMaterials: A total of 43 patients initially treated with an IMRT plan delivering 50 Gy to the prostate,
seminal vesicles, and pelvic lymph nodes, followed by a conformal radiotherapy (CRT) plan delivering 20 Gy to the
prostate and seminal vesicles, were studied. Dose–volume histogram (DVH) data for the added plans were
compared with dose–volume histogram data for the sum of two CRT plans for 15 cases. Gastrointestinal (GI)
and genitourinary (GU) toxicity, based on the Radiation Therapy Oncology Group scoring system, was recorded
weekly throughout treatment as well as 3 to 18 months after treatment and are presented.
Results: Treatmentwith IMRTboth reducednormal tissue doses and increased theminimum target doses. Intestine
volumes receivingmore than 40 and 50Gywere signiﬁcantly reduced (e.g., at 50Gy, from 81 to 19 cm3; p= 0.026), as
were bladder volumes above 40, 50, and 60 Gy, rectum volumes above 30, 50, and 60 Gy, and hip joint muscle vol-
umes above 20, 30, and 40 Gy. During treatment, Grade 2 GI toxicity was reported by 12 of 43 patients (28%), and
Grade 2 to 4 GU toxicity was also observed among 12 patients (28%). With 6 to 18 months of follow-up, 2 patients
(5%) experienced Grade 2 GI effects and 7 patients (16%) experienced Grade 2 GU effects.
Conclusions: Use of IMRT for pelvic irradiation in prostate cancer reduces normal tissue doses, improves target
coverage, and has a promising toxicity proﬁle.  2008 Elsevier Inc.
Prostate cancer, Lymph node irradiation, Intensity-modulated radiotherapy, Inverse planning, Acute effects.
INTRODUCTION
Experience with conformal radiotherapy (CRT) for prostate
cancer treatment has shown that reducing normal tissue
irradiation leads to lower rates of gastrointestinal (GI) and
genitourinary (GU) normal tissue toxicity (1–4). This has
spurred efforts to achieve further sparing of organs at risk
(OARs) to allow for dose escalation, in particular with the
introduction of intensity-modulated radiotherapy (IMRT).
Prostate cancer has been the major IMRT test site, mainly
investigated as a treatment option for patients with localized
disease where the prostate or prostate and seminal vesicles
are the targets. For prostate cancer patients at high risk for
involvement of pelvic lymph nodes, the Radiation Therapy
Oncology Group (RTOG) 9413 trial documented an
improved progression-free survival for these patients if the
pelvic lymph nodes were irradiated (5). Compared with local-
ized ﬁelds, however, pelvic irradiation carries the risk of
increasing adverse effects rates, in particular for the intestine
(5–8). Although the typical shape of the lymph node target
calls for use of IMRT (with the planning target volume
very close to the intestine), relatively few institutions have
yet reported on the application of IMRT for this subset of
prostate cancer patients (9–14). We have implemented
IMRT for this patient group with the aim of reducing the
normal tissue doses and toxicity, in particular those related
to intestine irradiation. In this report we present our proce-
dures for target volume deﬁnitions, optimization criteria,
and ﬁeld arrangements as well as our early experiences in
terms of resulting dose distributions and toxicities.
METHODS AND MATERIALS
Patients
Patient accrual to our prostate pelvic IMRT study started in
September 2005; and as of January 2007, 43 patients had completed
their RT course. Lymph node irradiation was indicated for patients
with either stage T3 or N+ disease (15). The clinical staging of the
Reprint requests to: Ludvig Paul Muren, Ph.D., Department of
Medical Physics, Aarhus University Hospital, Nørrebrogade 44,
Building 5, DK-8000 Aarhus C, Denmark. Tel: (+45) 8949 4450;
Fax: (+45) 89492530; E-mail: muren@as.aaa.dk
Conﬂict of interest: none.
Received Sept 15, 2006, and in revised form Nov 16, 2007.
Accepted for publication Nov 21, 2007.
1034
Int. J. Radiation Oncology Biol. Phys., Vol. 71, No. 4, pp. 1034–1041, 2008
Copyright  2008 Elsevier Inc.
Printed in the USA. All rights reserved
0360-3016/08/$–see front matter
doi:10.1016/j.ijrobp.2007.11.060
primary tumor was performed according to the 2002 TNM classiﬁ-
cation for prostate cancer (16), and the histopathologic specimens
were graded according to the Gleason pattern score (17). Patients
with distant metastases were excluded if positive ﬁndings were pres-
ent in the routine bone scan. All patients were at high risk according
to the criteria of Zelefsky et al. (2) and were given endocrine therapy
consisting of a 6-months course of luteinizing hormone–releasing
hormone analogue and antiandrogen (maximal androgen blockade).
Endocrine therapy commenced 2 to 3 months post-RT to exploit the
reduction of the prostate volume, and continued 3 to 4 months after
the start of RT (18). Relevant patient and tumor characteristics are
shown in Table 1.
Computed tomographic scanning and deﬁnitions of targets
and normal tissues
All patients underwent computed tomography (CT) scanning
(Prospeed SX Power, GE Medical Systems, Milwaukee, WI) and
were subsequently treated in supine position using knee and ankle
ﬁxation cushions (Sinmed BV, Reeuwijk, The Netherlands) for
immobilization. The CT scans extended from the L3/L4 vertebrae
down to the level of the perineum, with 5-mm thick slices with
5-mm intervals. Using our Eclipse treatment planning system (Var-
ian Oncology Systems, Palo Alto, CA) the responsible oncologist
contoured the prostate gland, the seminal vesicles, and the relevant
lymph nodes, and produced two sets of clinical target volumes
(CTV1 and CTV2) for the ﬁrst and second treatment phases, respec-
tively. Both CTV1 and CTV2 contained the prostate and the seminal
vesicles, whereas CTV1 also included pelvic lymph nodes, deﬁned
individually in each patient. In most cases it encompassed the
internal and external iliac vessels and a rim2.5 cmwide area along
the pelvic wall between these vessels. The presacral nodes were not
included. Positive para-aortal lymph nodes were considered as dis-
tant metastases. For both PTV1 and PTV2, a total margin of 15 mm
was applied around the prostate and seminal vesicles, except
posteriorly, where a 10-mm margin was used. No target localization
technique was used during treatment, but a portal imaging protocol
reducing systematic setup errors was followed, as explained later
here. The lymph nodes that were encompassed in PTV1 were
included with a 10-mm margin to account for delineation
uncertainty and setup accuracies; their internal motion was assumed
to be negligible.
The responsible oncologist also outlined the relevant OARs,
including intestine, bladder, rectum, penile bulb, hip joints, hip joint
muscles (gluteus maximus and minimus) and bony structures. The
intestine volume included all identiﬁable small and large intestine
segments, not including the rectum. The bladder was outlined
from apex to dome, whereas the rectosigmoid ﬂexure was applied
as the superior/cranial limit of the rectum and the anal verge as
the inferior/caudal limit. Both the rectum and bladder were deﬁned
as the volumes within the respective outer wall contour, including
contents. The outlined hip joint structure included 5 mm on both
sides of the joint itself. The intestine, bladder, and rectum volumes
were used actively in the optimization, as these were considered to
be the dose-limiting OARs. All volumes were based on the planning
scan situation only, and no attempts were made to account actively
for the motion of these organs; this issue is the topic for ongoing
projects at our institution.
Field arrangements and optimization criteria
The RT course for all patients consisted of an initial IMRT plan
delivering 50 Gy to PTV1 (prostate, seminal vesicles, and lymph
nodes with margins) followed by a four-ﬁeld CRT plan delivering
20 Gy to PTV2 (prostate and seminal vesicles with margins), both
plans delivered in daily 2-Gy fractions, 5 days per week. For the
IMRT plan used in the ﬁrst phase of the treatment (to 50 Gy),
a seven-ﬁeld beam arrangement with gantry angles 0, 51, 103,
154, 206, 257, and 309 was applied for all patients because of
the complexity of the PTV shape, using in most cases 15-MV
photon beam quality. A collimator angle of 2 was used for all
beams to reduce tongue-and-groove effects. The same isocenter
was used throughout treatment, including the four-ﬁeld conformal
plan used for the second phase (the last 20 Gy). All treatment
planning and optimization was performed using Eclipse. Patients
were treated on one of three Varian Clinacs, all equipped with
a Millennium MLC-120 multileaf collimator. Intensity modulation
was achieved using the sliding window technique.
During the optimization, the minimum PTV1 dose criterion was
given the highest priority. To ensure adequate target coverage
(aiming for a minimum point dose of 95% in the PTV1), the optimi-
zation criteria for PTV1 were applied on an enlarged volume, the
PTV1 extended with 3 mm in the anterior/posterior/left/right direc-
tions and 5 mm in the superior/inferior directions. Good dose con-
formality was secured by reducing as far as possible the volume
outside the extended PTV1 that receivedmore than 95% of the target
dose. For the main OARs (the intestine, bladder, and rectum), the
optimization criteria were based on what could be achieved with
a traditional conformal four-ﬁeld plan for the PTV1. For all patients
this conformal plan consisted of two opposing anterior and posterior
beams and two opposing lateral beams (gantry angles 0, 90, 180,
and 270), with the multileaf collimator shapes conforming to the
projections of the PTV1. In the optimization we aimed to reduce
the volumes of these organs receiving doses greater than 30, 40,
and 50 Gy. For each individual patient we applied DVH points
corresponding to 50%, 25%, and 25% volume reductions relative
to this four-ﬁeld CRT plan as initial DVH constraints for the
intestine, rectum, and bladder, respectively, reﬂecting our aim to
prioritize reduction of intestinal doses.
Analysis of dose–volume histograms
Dose–volume histograms (DVHs) were calculated for the IMRT
plan up to 50 Gy, as well as for the total treatment plan (to 70 Gy),
Table 1. Characteristics of study patients
No. of patients 43
Median age (years) 66
Age range (years) 66
Concurrent cardiovascular disease 14 (33%)
Clinical stage
T1 0
T2 3 (7%)
T3 36 (84%)
T4 3 (7%)
Tx 1 (2%)
Gleason sum
#6 7 (16%)
$7 33 (77%)
Unknown 3 (7%)
PSA (ng/l)
<4 2 (4%)
4–10 11 (26%)
10.1–20 11 (26%)
>20 19 (44%)
Endocrine treatment 43 (100%)
Abbreviation: PSA = prostate-speciﬁc antigen.
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for all deﬁned volumes (i.e., intestine, bladder, rectum, penile bulb,
hip joints, and hip joint muscles) in the 15 patients treated consecu-
tively between February and July 2006. To quantify the beneﬁt of
the IMRT plans actually applied, we also calculated the correspond-
ing DVHs for the traditional conformal plan both for the initial phase
and both phases combined, using the same dose prescription
protocol.
Patient-speciﬁc quality assurance
For all patients included in this study we veriﬁed experimentally
both the absolute dose in a dedicated IMRT phantom as well as the
ﬂuency of the individual treatment ﬁelds. To allow absolute dose
veriﬁcation, dose calculations were performed in Eclipse by trans-
ferring the treatment ﬁelds used for the patient onto a CT study of
a dedicated IMRT phantom (Universal IMRT veriﬁcation phantom,
type 40020, PTW, Freiburg, Germany), positioning the ﬁelds to
enable the active detector volume to be inside the high-dose volume.
The gantry and collimator angles of all beams were reset to 0, and
the absolute calculated dose resulting from each individual ﬁeld was
recorded. Absolute dose measurements were performed by deliver-
ing these IMRT ﬁelds when having a PTW 0.125 cm3 ionization
chamber in one of the detector slots, measuring the dose delivered
by each individual ﬁeld. All patients except 2 with marginal viola-
tions fulﬁlled the acceptance criteria of 4% used on the total absolute
dose, with a mean dose difference of0.6% 1.5%. For the last 31
patients the dose calculation accuracy was improved, and the total
dose measured in the initial attempt was within 3.2% of calculations
and within 2% for 29 of these patients.
The ﬂuency veriﬁcation was performed ﬁeld by ﬁeld using the
Varian Portal Vision amorphous silicone detector (aS500 and
aS1000, Varian Medical Systems) positioned in 105-cm source-
to-detector distance, and delivering the actual treatment beams
onto the detector plate. The measured intensity distribution for
each ﬁeld was compared with the predicted ﬂuency distribution,
derived using the pencil beam Portal Dose Prediction software inte-
grated in the Eclipse/Vision system (19). A gamma evaluation tool,
incorporating both differences in dose relative to the maximum dose
as well as distance to agreement, was used with acceptance criteria
of 4% in dose difference and 4-mm in distance to agreement for 99%
of the detector area. For some patients the comparison was per-
formed after normalization of the ﬂuencies because of problems
with the calibration for one of the detectors. The acceptance criteria
were then reduced to 3% and 3 mm. With this approach, these
criteria were fulﬁlled in all patients except one ﬁeld in 1 patient.
Ion chamber veriﬁcation alone was performed in 2 patients because
of technical problems with one of the detectors.
Patient positioning
All patients followed the patient positioning procedures that we
apply for all radically treated RT patients (except those receiving
daily on-board imaging-based adaptive RT), with front and lateral
electronic portal images acquired daily over the ﬁrst four treatment
fractions followed by weekly imaging for the remaining part of the
treatment course. Bony structures in the portal images were matched
to the bony anatomy in the digitally reconstructed radiographs.
Toxicity scoring
The RTOG toxicity scoring system was used to grade lower GI
and GU morbidity during and after the course of treatment (20).
Patients were scheduled for weekly assessments of symptoms dur-
ing the course of therapy (after 10, 20, 30, 40, 50, 60, and 70 Gy)
by the responsible oncologist in Weeks 3 and 6, and by the
radiographers at the treatment unit in the remaining weeks; consis-
tency was secured by thorough instructions/training of the involved
radiographers (by the responsible oncologist). For practical reasons,
the acute effects were scored on average ﬁve times during treatment;
19 of the 43 patients were seen seven times. In addition patients were
enrolled onto a 5-year follow-up scheme, with the ﬁrst session
scheduled 3 months after treatment. Anal symptoms were scored
using the modiﬁed scoring system of Koper et al. (21), and were
joined with the GI score. In general the GI or GU symptoms that
needed medical prescriptions were scored as Grade 2 or greater
toxicity. By end of July 2007, all cases had at least 6 months of
follow-up time; 21 patients had been seen 12 months post-RT and
2 had been seen 18 months post-RT. The symptoms reported on
these follow-up sessions will be presented here.
RESULTS
DVH analysis
The changes in normal tissue doses resulting from use of
IMRT instead of CRT (for the ﬁrst phase of treatment) are
shown in Table 2, comparing DVH parameters for both
phases of the treatment combined. Intestine, bladder, and
rectum DVH constraints were included in the optimization,
and hence the largest and most systematic changes were
seen for these three organs as well as the hip joint muscles.
For the intestine, the use of IMRT led to a considerable
decrease in the absolute volumes receiving doses greater
than 40 to 60 Gy; e.g., at 50 Gy, the average volume
decreased from 81 to 19 cm3 (p < 0.001). However there
was an increase in the volumes receiving doses greater than
20 Gy. For the bladder, we also obtained considerable vol-
ume reductions for the doses in the range of 40 to 60 Gy
(e.g., from 87% to 64% >50 Gy). For this organ, there was
also a small but statistically signiﬁcant increase in volumes
receiving more than 70 Gy. The volumes of rectum above
all dose levels from 20 Gy to 60 Gy were reduced with
IMRT, and again the difference seemed to be largest at the
level of 50 Gy. With either technique, only a very small
part of the rectum received 70 Gy in approximately one
third of the patients. Regarding the three other OARs that
were not included in the optimization, use of IMRT led
to a slight increase in doses to the penile bulb and the
hip joints but reduced the doses to the hip joint muscles.
For the penile bulb there was an increase in the volumes re-
ceiving more than 60 Gy, which probably resulted from the
close proximity between this structure and the target vol-
umes. For the hip joints, use of IMRT increased volumes
receiving more than 40 to 50 Gy, whereas the volumes of
the hip joint muscles receiving more than 20 to 40 Gy
decreased considerably.
For the target volumes (both PTV1 and PTV2), use of
IMRT increased the average minimum target doses (from
45.5 to 47.4 Gy for PTV1, p < 0.001, and from 62.2 to
64.6 Gy for PTV2, p < 0.001). The same mean dose was
prescribed for both techniques, but as the dose was normal-
ized to the ITV, the mean doses in the PTVs increased
slightly after the improved coverage of the PTVs.
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As the second phase was delivered with the same (CRT)
plan for both alternatives, the reduction in normal tissue
doses obtained with IMRT was even clearer when comparing
the ﬁrst-phase plans separately (Fig. 1). For the ﬁrst-phase
plans, use of IMRT reduced intestine volumes receiving
more than 40 to 50 Gy, rectum volumes receiving more
than 20 to 50 Gy, and bladder volumes receiving more than
30 to 50 Gy. For example, the average intestine volume of
more than 50 Gy was reduced from 48 to 3 cm3, the average
bladder volume of more than 40 Gywas reduced from 90% to
67%, and the average rectum volume of more than 40 Gy was
reduced from 68% to 52%.
Adverse effects within 18 months post-treatment
No Grade 3 or higher GI adverse effects were observed
among the patients. During the treatment course, acute Grade
2 GI effects were reported by 12 of 43 patients (28%),
whereas Grade 1 GI adverse effects were reported by
22 patients (51%). These symptoms generally consisted of
increased frequency of bowel movement, change in stool
consistency, rectal discomfort, tenesmus, and urgency.
Nine patients (21%) did not experience any GI adverse
effects during treatment. Regarding acute GU effects, bladder
catheterization was required in 1 patient during the third
week of treatment, and this was scored as a Grade 4 effect.
Otherwise, Grade 2 GU effects were observed among 12 of
43 patients (28%) and Grade 1 effects among 24 (56%).
The symptoms reported included increased urinary
frequency, urgency, dysuria, and nocturia. Six patients
(14%) did not experience any GU adverse effects during
treatment.
With a follow-up of 6 to 18 months post-RT (median, 12
months), the highest GI adverse effect score was Grade 2
in 2 patients (5%) and Grade 1 in 20 patients (47%). Apart
from 1 patient who developed ﬁrst renal and subsequently
bladder cancer and had related GU symptoms (scored as
Grade 3), Grade 2 was the highest score also for the GU
effects and was observed in 7 patients (16%), and Grade 1
GU was scored in 13 patients (30%). Of the 21 patients
seen 12 to 18 months post-RT, only 1 patient (5%) had Grade
2 GI effects and 1 patient (5%) had Grade 2 GU effects as of
their last consultations.
DISCUSSION
In this report, we have presented our planning and veriﬁca-
tion procedures as well as our early clinical experiences from
a study of prostate and lymph node IMRT. We found that use
of IMRT reduces the doses to important OARs such as the
intestine, bladder, and rectum when treating pelvic lymph
nodes, while also improving target coverage. Clinical
outcomes observed thus far are also promising, with a very
low GI toxicity proﬁle in particular.
A characteristic feature of IMRT and inverse planning is
the trade-off between target coverage and normal tissue
sparing. In this series we have given the highest priority to
obtaining at least as good target coverage as in the standard
plan, followed by reducing the doses to the intestine; this is
also reﬂected in the DVH results. Although there are limited
CT-based DVH constraints for the intestine (22, 23), it seems
very likely that the reductions in intestine volumes that we
obtained at both 40 Gy (from 139 to 89 cm3) and 50 Gy
(from 81 to 19 cm3) are clinically meaningful. For example,
according to Gallagher et al., less than 78 cm3 of the small
intestine should receive more than 45 Gy, and less than 17
cm3 should receive 50 Gy (22). The acute adverse effect
outcome of the present IMRT series (28% of both Grade 2
GI and GU adverse effects) compare well with our previous
CRT experience using the same prescription dose level, in
which 40% of the CRT patients had acute Grade 2 GI and
Table 2. Comparison of dose–volume histogram (DVH)
parameters for intestine, bladder, rectum, penile bulb, hip
joints and hip joint muscles for the total treatment (both
phases) for conformal radiotherapy (CRT) versus intensity-
modulated radiotherapy (IMRT) plans
DVH parameter CRT IMRT p Value
Intestine (cm3)
Volume >20 Gy 264 (54-628) 281 (63–678) 0.005
Volume >30 Gy 177 (46–459) 182 (38–483) 0.13
Volume >40 Gy 139 (32–328) 89 (18–248) <0.001
Volume >50 Gy 81 (2–214) 19 (0–77) <0.001
Volume >60 Gy 3 (0–29) 2 (0–20) 0.043*
Volume >70 Gy 0 0 —
Bladder (%)
Volume >20 Gy 100 (100–100) 100 (100–100) 0.32*
Volume >30 Gy 100 (95–100) 98 (94–100) 0.02
Volume >40 Gy 95 (79–100) 84 (67–100) <0.001
Volume >50 Gy 87 (64–100) 64 (32–98) <0.001
Volume >60 Gy 54 (21–95) 45 (18–83) <0.001
Volume >70 Gy 0 (0–1) 1 (0–5) 0.007*
Rectum (%)
Volume >20 Gy 98 (93–100) 97 (92–100) <0.001
Volume >30 Gy 96 (89–100) 94 (85–99) <0.001
Volume >40 Gy 84 (71–92) 75 (62–89) <0.001
Volume >50 Gy 67 (45–88) 51 (34–67) <0.001
Volume >60 Gy 36 (23–51) 29 (17–39) <0.001
Volume >70 Gy 0 (0–5) 0 (0–1) 0.44*
Penile pulb (%)
Volume >20 Gy 91 (50–100) 90 (45–100) 0.16
Volume >30 Gy 84 (40–100) 83 (36–100) 0.32
Volume >40 Gy 75 (31–100) 74 (27–100) 0.56
Volume >50 Gy 62 (18–100) 62 (16–100) 0.72
Volume >60 Gy 40 (1–99) 48 (6–99) <0.001
Volume >70 Gy 0 0 —
Hip joint (%)
Volume >20 Gy 99 (92–100) 100 (99–100) 0.03
Volume >30 Gy 86 (50–100) 87 (67–99) 0.49
Volume >40 Gy 44 (9–72) 51 (19–67) 0.06
Volume >50 Gy 6 (0–20) 11 (0–21) 0.04
Volume >60 Gy 0 (0–4) 0 (0–2) 0.77*
Volume >70 Gy 0 0 —
Hip joint muscles (%)
Volume >20 Gy 66 (54–75) 40 (22–59) <0.001
Volume >30 Gy 36 (14–54) 7 (1–18) <0.001
Volume >40 Gy 7 (1–17) 0 (0–3) <0.001
Volume >50 Gy 0 0 —
Data are means (ranges).
* Nonparametric Wilcoxon test applied; p values are derived
from two-sided paired statistical tests.
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35% had acute Grade 2 GU adverse effects (6, 24). Also the
late adverse effect rates observed at the ﬁrst follow-up
consultations after treatment seem reasonable, in particular
for the GI effects. Again, comparing our previous CRT expe-
rience in which 11% of patients had at most Grade 2 late GI
effects and 9% had at most Grade 2 late GU effects during
their 6- and 12-month consultations, the corresponding
values of 5% and 16% (with the same median follow-up
times) in the present series seem comparable and, again,
most favorable for the GI effects. These results also seem
to be similar to those in previous IMRT studies in this patient
group. In a retrospective study from the Memorial Sloan-
Kettering Cancer Center in a series of 27 patients, of whom
13 actually had received IMRT, the average intestinal
volumes receiving more than 45 Gy (i.e., the prescription
dose to the lymph node volume) was reduced from 23%
with CRT to 9% with IMRT, considering the ﬁrst phase of
treatment alone (14). Clinical outcomes for the IMRT
patients were also good; in the acute phase, only 1 patient
experienced acute Grade 2 GI effects and 4 patients experi-
enced acute Grade 2 GU effects; there were no late Grade 2
effects observed among these patients, who all had more
than 10months of follow-up (14). In an IMRT planning study
corresponding to the ﬁrst phase in the current analysis,
Nutting et al. also obtained considerable sparing of intestine,
bladder, and rectum using IMRT instead of CRT, e.g.,
a reduction from 18% to 5% of the intestine receiving more
than 45 Gy (25). This planning study was also the basis for
a clinical dose escalation study of pelvic IMRT cases at the
Royal Marsden Hospital, where the doses to the two deﬁned
lymph node targets (negative and positive nodes) were
increased in two 5-Gy steps. Initial clinical experience
(with 50 Gy to the negative and 55 Gy to the positive lymph
nodes) were more or less in line with our data, with 2 patients
experiencing Grade 2 GU effects and 6 experiencing Grade 2
GI effects within a median follow-up of 7 months (26).
Although the pelvic anatomy obviously differs between
men and women, considerable sparing of normal tissues
has been documented also for pelvic irradiation in patients
with gynecologic cancer, avoiding Grade 3 GI toxicity and
reducing the rate of Grade 2 toxicity (27, 28).
Considering the deﬁnition and inclusion of lymph nodes
for various stages of prostate cancer there are not yet any pub-
lished consensus guidelines. The 2003 report from the RTOG
9413 study, which shows a clear beneﬁt of lymph node irra-
diation for patients receiving adjuvant hormone therapy (5,
8), should increase the use of pelvic RT for these patients,
and hence should also highlight the need for lymph node
treatment guidelines (29). In addition, noninvasive methods
such as magnetic resonance imaging with superparamagnetic
Fig. 1. Comparison of dose distributions of the ﬁrst phase of the treatment with conformal radiotherapy (left) and intensity-
modulated radiotherapy (right) in the upper (upper) and lower (lower) pelvis. Target volumes shown in red; intestine, pink;
bladder, yellow; and rectum, blue. Dose color wash is from 25 Gy (dark blue) to 50 Gy (red).
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nanoparticle contrast, choline–positron emission tomogra-
phy, and single photon emission computed tomography are
now being used to deﬁne positive lymph nodes (7, 30–33).
It should therefore become possible to test further reﬁnement
in the dose prescription pattern for the lymph nodes that
could be delivered with IMRT.
The RT scheme used for the patient series described in this
report involves two phases. A major advantage of IMRT is
that it opens the possibilities for concomitant delivery of
different doses to different target volumes, e.g., combining
two-phase treatments using integrated boosts as well as local
dose escalation (34–37). For the current patient group, we
have recently introduced a Phase II study in which we
simultaneously treat both the pelvic lymph nodes (with con-
ventional fractionation, i.e., 2 Gy per fraction) combined with
hypofractionated doses (2.4–2.7 Gy per fraction) to the pros-
tate and seminal vesicles (38, 39). Following head-and-neck
cancer practice, the doses prescribed to the pelvic lymph
nodes could have been differentiated, with a higher dose to
positive or radiologically suspect lymph nodes. It also seems
justiﬁed to introduce yet another dose differentiation, as
a higher dose could be prescribed to either the whole prostate
(e.g., without margins) or to parts of the prostate, in the latter
situation guided by magnetic resonance imaging or magnetic
resonance spectroscopy (40, 41) or by positron emission
tomography or computed tomography (42). In a recent study,
Jacob et al. showed considerable beneﬁt, in terms of
biochemical control, from prescribing doses greater than
70 Gy to intermediate and high-risk prostate cancer patients
(43). However attempts to derive alternative fractionation
schedules using IMRT-delivered one-phase integrated boost
approaches are complicated by their dependence on the cur-
rently unsettled radiobiologic parameters for prostate cancer,
such as the sensitivity to changes in fraction sizes (i.e., the a/
b ratio) as well as the sensitivity to changes in overall treat-
ment time (i.e., Tk and Dprolif) (44–50). Such fractionation
schedules should therefore be tested within the settings of
carefully controlled trials.
The IMRT planning presented in this report is based on the
planning CT scan only, which is typically acquired 1 week
before the start of treatment. Given the considerable pelvic
organ motion, this necessitated the use of relatively wide
target volume margins. However we have used gold ﬁducials
for localized prostate cancer patients for several years, and
this procedure has now also been introduced for patients
with locally advanced prostate cancer (within the above-
mentioned simultaneous integrated IMRT protocol), allow-
ing for a considerable margin reduction. In addition, basing
the treatment on a single planning scan obviously leads to
uncertainty in the normal tissue DVH parameters, and this
is currently being investigated in a study at our institution
in which repeated CT and OAR contour data are introduced.
However, because of the good dose conformality obtained
with IMRT, it seems reasonable to assume that the IMRT
plans are still superior also when accounting for organ
motion. Furthermore we are developing methods to account,
in particular, for the intestine motion in pelvic IMRT. As an
initial step we have quantiﬁed the size of intestine planning
organ at risk volume margins (51). Because there seem to
be distinct probability patterns (albeit individual) of the posi-
tion/location of the intestine throughout the treatment course
(51), we are currently initiating an investigation of the poten-
tial of the coverage probability concept (52) in planning pel-
vic IMRT. Ultimately such sophisticated planning methods
should be combined with adaptive, image-guided radiation
therapy–based methods through frequent acquisition of
cone-beam CT scans during treatment.
As the follow-up time of this IMRT cohort increases, it
will be interesting to see the time course of the late toxicity.
The clinical outcome data collected will be compared with
the results from a prospectively followed cohort of 247
patients with localized and locally advanced prostate cancer
treated with CRT during 2000 to 2001, now with more
than 5 years of follow-up.
CONCLUSION
Use of IMRT for treatment of pelvic lymph nodes in pros-
tate cancer leads to considerably reduced irradiation of OARs
such as the intestine, bladder, and rectum, while at the same
time improving target coverage. The preliminary clinical out-
comes experienced so far are also promising, and have en-
couraged us to pursue further target dose escalation for
these patients.
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